The artificial intelligence (AI) in pharmaceutical market is expanding rapidly as the industry applies AI to drug development and clinical trial optimization. Polaris Market Research reports that the market was valued at USD 2.48 billion in 2025, with USD 3.24 billion estimated for 2026, and is projected to reach USD 28.63 billion by 2034, a CAGR of 31.2% from 2026 to 2034. Growing awareness of AI among pharma manufacturers and rising adoption in research and development are driving this growth.

Why AI Matters to Pharma R&D

Pharma companies use machine learning algorithms and AI-powered tools to accelerate drug discovery. AI helps companies identify drug targets, analyze protein structures and simulate chemical interactions with greater precision, and it can test millions of molecular combinations much faster than traditional methods. The report cites MIT research showing that only 13.8% of medications make it through clinical testing, and notes that a company may pay anywhere from USD 161 million to USD 2 billion to bring a medicine through the full clinical trial process and receive FDA approval. AI promises to raise success rates, reduce costs and lower operational expenses.

The growing complexity of modern pharmacology has increased demand for AI in pharmaceutical solutions. Polaris adds that AI in pharmaceutics can save money and effort while giving a greater understanding of interactions between compositions and process parameters, with uses spanning smart manufacturing, automated control processes and predicting new treatments.

Technology Segments

By technology, the market includes machine learning, natural language processing and deep learning. The natural language processing segment led with a 35.64% revenue share in 2025 and is expected to maintain its dominance, because it translates data into a narrative form that medical experts and patients can understand and supports the interpretation of insights for healthcare decisions.

Deep learning models support molecular modeling and protein structure prediction, while machine learning identifies patterns in complex biological data. Polaris also notes a tremendous rise in the adoption of generative AI, which can create new molecular structures, speed up the identification of drug candidates and help researchers predict the potential of new drugs.

Cloud Deployment Gains Preference

By deployment mode, the market is split into cloud and on-premises, and the cloud segment accounted for the largest share in 2025. Startups and small to medium-sized enterprises face constant pressure to lower costs and maximize ROI. On-premises systems require large upfront investment in hardware, infrastructure maintenance and IT staff, whereas cloud deployment provides AI services on a pay-per-use basis and removes those expenses.

Application and End-Use Coverage

The report covers applications including drug discovery, precision medicine, medical imaging and diagnostics, and research. End users include pharmaceutical and biotechnology companies, hospitals and diagnostic centers, and academic and research institutes.

Browse In-depth Market Research Report:

https://www.polarismarketresearch.com/industry-analysis/artificial-intelligence-ai-in-pharmaceutical-market 

Regional Leadership

North America led the market with a 49.80% revenue share in 2025, supported by leading pharmaceutical companies, strong healthcare infrastructure and high investment in AI and biotechnology. The U.S. remains the main hub for pharmaceutical AI startups and partnerships between biotech and AI companies. Asia Pacific is expected to grow fastest, driven by biotechnology research, healthcare investment and government initiatives in China, India and South Korea.

On the supply side, offerings are segmented into hardware, software and services. Major pharmaceutical companies and technology providers are forming strategic collaborations, and growing investment in AI technology, cloud-based pharmaceutical analytics and computational drug discovery is shaping the competitive landscape.

Key Players

• AstraZeneca LLC
• Atomwise Inc.
• Bayer AG
• Cloud Pharmaceuticals Inc
• GNS Healthcare
• IBM Watson
• Merck & Co.
• Microsoft Corporation
• Novartis AG
• NVIDIA Corporation
• Pfizer Inc.
• Recursion Pharmaceuticals Inc.
• XtalPi Inc.

Conclusion

The global Artificial Intelligence (AI) in Pharmaceutical Market is expanding as pharmaceutical companies increasingly adopt advanced technologies to improve drug discovery, development, clinical research, and commercialization. Traditional drug development processes can require significant amounts of time, financial investment, and research resources, creating strong demand for technologies that can improve efficiency. AI can analyze large and complex datasets, identify potential drug candidates, support molecular research, predict drug interactions, and assist researchers in making data-driven decisions. AI is also being explored for clinical trial design, patient recruitment, data analysis, and personalized treatment development. The growing availability of healthcare data, increasing investment in biotechnology, and advancements in machine learning are further supporting the integration of AI across pharmaceutical operations.

More Trending Latest Reports By Polaris Market Research:

Waste Recycling Services Market

Aesthetic Medicine Market

Specialty Chemicals Market

Home Healthcare Market

Palletizer Market

Bacterial & Viral Specimen Collection Market

Bacterial & Viral Specimen Collection Market

Specialty Chemicals Market

Sodium-ion Battery Market